01371nas a2200253   4500000000100000008004100001260001200042653002500054653001600079653001200095653001800107653001400125100001300139700001500152700002200167700001400189700001100203700001100214245007400225856005000299490000700349520074700356022001401103       2020                            d  c12/202010aMycobacterium leprae10aclofazimine10adapsone10ananoparticles10atargeting1 aChaves L1 aPatriota Y1 aSoares-Sobrinho J1 aVieira AC1 aLima S1 aReis S00aDrug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?  uhttps://www.mdpi.com/1999-4923/12/12/1202/htm0 v123 a<p>Leprosy disease remains an important public health issue as it is still endemic in several countries. , the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.</p>  a1999-4923